Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7381 to 7395 of 7707 results

  1. Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID5093]

    Discontinued [GID-TA10995]

    Technology appraisal guidance
    Discontinued

  2. Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]

    Discontinued [GID-TA11108]

    Technology appraisal guidance
    Discontinued

  3. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    Discontinued [GID-TA10937]

    Technology appraisal guidance
    Discontinued

  4. Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]

    Discontinued [GID-TA10965]

    Technology appraisal guidance
    Discontinued

  5. Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]

    Discontinued [GID-TA10863]

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    Discontinued [GID-TA10766]

    Technology appraisal guidance
    Discontinued

  7. Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]

    Discontinued [GID-TA11004]

    Technology appraisal guidance
    Discontinued

  8. Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]

    Discontinued [GID-TA11020]

    Technology appraisal guidance
    Discontinued

  9. Filgotinib for treating moderately to severely active Crohn's disease [ID6236]

    Discontinued [GID-TA11244]

    Technology appraisal guidance
    Discontinued

  10. Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID5075]

    Discontinued [GID-TA10958]

    Technology appraisal guidance
    Discontinued

  11. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued [GID-TA10583]

    Technology appraisal guidance
    Discontinued

  12. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID1251]

    Discontinued [GID-TA10525]

    Technology appraisal guidance
    Discontinued

  13. Ibrutinib for untreated mantle cell lymphoma [ID1221]

    Discontinued [GID-TA10185]

    Technology appraisal guidance
    Discontinued

  14. Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

    Discontinued [GID-TA10502]

    Technology appraisal guidance
    Discontinued

  15. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued [GID-TA11255]

    Technology appraisal guidance
    Discontinued